Clinical Trial Update: A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) [Phase 3]

View source ↗

Summary

Phase 3 study assessing pazopanib with or without abexinostat in locally advanced or metastatic renal cell carcinoma; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Abexinostat (Abexinostat)
• Pazopanib (Pazopanib)

Snippet

Sponsor: Xynomic Pharmaceuticals, Inc. | Conditions: Renal Cell Carcinoma | Phase 3 | Status: RECRUITING